Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
New England Journal of Medicine · 06.02.2025 · 392 (6) · 619-621
DOI: 10.1056/nejmc2414705 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 06.02.2025. Verfasst von Byoung C Cho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Yonsei University College of Medicine, Seoul, South Korea. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Yonsei University College of Medicine, Seoul, South Korea.
- Janssen Research and Development, Spring House, PA.
- Virginia Cancer Specialists, Fairfax, VA.
Zitieren
APA
Cho, B. C., Sethi, S., & Spira, A. I. (2025). Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC. New England Journal of Medicine, 392(6), 619-621. https://doi.org/10.1056/nejmc2414705
Vancouver
Cho BC, Sethi S, Spira AI. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC. New England Journal of Medicine. 2025;392(6):619-621. doi:10.1056/nejmc2414705
BibTeX
@article{Cho2025,
author = {Cho, Byoung C and Sethi, Seema and Spira, Alexander I},
title = {Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC},
journal = {New England Journal of Medicine},
year = {2025},
volume = {392},
number = {6},
pages = {619--621},
doi = {10.1056/nejmc2414705}
}
EUVIMED